- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05407168
Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool (iDECIDE)
Improving Decision-Making Encounters in Lung Cancer (I DECide) II: A Randomized Control Trial Of A Low-Literacy Conversation Tool
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Conduct a randomized, controlled trial evaluating the efficacy of a conversation tool on patient-centered health and decision-making outcomes among patients making lung cancer treatment decisions. A subset of participants from control and intervention groups will also have their clinic conversations with providers recorded II. Conduct in-depth, semi-structured qualitative audio or video recorded interviews among a subset of Aim 1 participants.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients review decision aid.
GROUP II: Patients receive standard of care.
After completion of study intervention, patients are followed up at 2 weeks, 3 months, and 6 months.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oregon
-
Hillsboro, Oregon, United States, 97123
- Recruiting
- Hillsboro Medical Center
-
Contact:
- Donald Sullivan, MD, MA, MCR
- Phone Number: 58087 503-220-8262
- Email: sullivad@ohsu.edu
-
Principal Investigator:
- Donald Sullivan, MD, MA, MCR
-
Portland, Oregon, United States, 97239
- Recruiting
- OHSU Knight Cancer Institute
-
Contact:
- Donald R Sullivan, MD, MA, MCR
- Phone Number: 58087 503-220-8262
- Email: sullivad@ohsu.edu
-
Principal Investigator:
- Donald R Sullivan, MD, MA, MCR
-
Portland, Oregon, United States, 97239
- Recruiting
- Portland VA Medical Center
-
Contact:
- Donald R Sullivan, MD, MA, MCR
- Phone Number: 58087 503-220-8262
- Email: sullivad@ohsu.edu
-
Principal Investigator:
- Donald R Sullivan, MD, MA, MCR
-
Portland, Oregon, United States, 97216
- Recruiting
- Adventist Health Portland
-
Contact:
- Donald Sullivan, MD, MA, MCR
- Phone Number: 58087 503-220-8262
- Email: sullivad@ohsu.edu
-
Principal Investigator:
- Donald Sullivan, MD, MA, MCR
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- AIM 1: Suspected lung cancer
- AIM 1: English fluency
- AIM 1: > 6-month life expectancy
- AIM 1: Score of ≥ 3 on the cognitive impairment screener
- AIM 2 PARTICIPANTS: Participation in Aim 1
- AIM 2 CLINICIANS: Discussing lung cancer treatment decisions with Aim 1 participants
- VA-SPECIFIC REQUIREMENT (inclusion of non-Veterans): Non-Veterans will be recruited for this study. Non-Veterans are an important component to this project since they will provide outside perspective. In this way, results of this study will be more generalizable
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group I (decision aid)
Patients review decision aid.
|
Ancillary studies
View decision aid
|
Active Comparator: Group II (standard of care)
Patients receive standard of care.
|
Ancillary studies
Receive standard of care
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decision Satisfaction
Time Frame: Up to 6 months
|
Will be assessed using two scales: 1) The Decisional Conflict Scale, which contains 16 items.
Higher scores indicate higher decisional conflict.
2) The Decisional Self-Efficacy Scale, which contains 11 items.
Higher scores indicate higher self-efficacy.
|
Up to 6 months
|
Efficacy of a conversation tool on patients' knowledge of lung cancer
Time Frame: Up 6 months
|
Will be assessed using nine questions from previously validated measures.
|
Up 6 months
|
Satisfaction with Communication/Confidence in Decision
Time Frame: Up to 6 months
|
Will be assessed using the 20-item COMRADE scale.
Higher scores indicate better outcomes.
|
Up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional Assessment of Cancer Therapy -- Lung scale
Time Frame: Up to 6 months.
|
Will be assessed by the Functional Assessment of Cancer Therapy -- Lung scale.
This scale has 27 items.
Higher scores indicate higher quality of life.
|
Up to 6 months.
|
Depression/Anxiety
Time Frame: Up to 6 months
|
Will be assessed using the 4 item Patient Health Questionnaire for Anxiety and Depression scale.
Scores greater than or equal to 3 on the first two questions suggest anxiety, and scores greater than or equal to 3 on the last two questions suggest depression.
|
Up to 6 months
|
Participation in Decision-Making
Time Frame: Up to 6 months
|
Will be assessed using the 2-item Control Preferences Scale.
Answers of 1 or 2 on both items are categorized as "patient controlled", answers of 3 are categorized as "shared", and answers of 4 or 5 are categorized as "physician-controlled."
|
Up to 6 months
|
Decision Regret
Time Frame: Up to 6 months
|
Will be assessed using the 5-item Decision Regret Scale.
Higher scores indicate high regret.
|
Up to 6 months
|
Quality of Communication
Time Frame: Up to 6 months
|
Will be assessed using the ~30 item Patient Assessment of cancer Communication Experiences scale.
Higher scores indicate higher perceived quality of communication.
|
Up to 6 months
|
Number of Palliative Care Referrals
Time Frame: Up to 6 months
|
Will be assessed by conducting chart review
|
Up to 6 months
|
Treatment Decision-Making Concordance
Time Frame: Up to 6 months
|
Will be assessed by observing the treatment received and the treatment most aligned with responses to the conversation tool.
If the treatment received is the same treatment the patient preferred according to the conversation tool, the treatment decision will be considered concordant.
|
Up to 6 months
|
Acceptability
Time Frame: Up to 6 months
|
Will be assessed using the Ottawa Acceptability scale for patients in the intervention group only.
|
Up to 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Donald R Sullivan, MD, MA, MCR, OHSU Knight Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00023160 (Other Identifier: OHSU Knight Cancer Institute)
- NCI-2021-09819 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Carcinoma
-
National Cancer Institute (NCI)CompletedLung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Adenosquamous Lung Carcinoma | Bronchioloalveolar Carcinoma | Large Cell Lung Carcinoma | Squamous Cell Lung CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Aging (NIA)RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Advanced Lung Non-Small Cell Carcinoma | Advanced... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedCarcinoma, Non-Small Cell Lung | Carcinoma, Small-Cell LungUnited States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Aging (NIA)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Advanced Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Unresectable Lung CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
University Hospital, LimogesGroupe Français de Pneumologie Cancérologie (GFPC)CompletedNon Small Cell Lung CarcinomaFrance
-
Massachusetts General HospitalCompletedSmall Cell Lung Carcinoma | Non-small Cell Lung CarcinomaUnited States
-
Shenzhen People's HospitalUnknownCarcinoma, Non-Small Cell Lung | Carcinoma, Small Cell LungChina
-
Pathway GenomicsTerminatedLung Neoplasms | Lung Cancer | Adenocarcinoma of the Lung | Cancer of the Lung | Small Cell Carcinoma of the Lung | Non Small Cell Carcinoma of the LungUnited States
-
National Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Lung Small Cell CarcinomaUnited States
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation